Repros Theraup (NASDAQ:RPRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Results 1 - 18 of 18

Recs

0
Member Avatar oscillation (27.54) Submitted: 1/24/2016 7:39:52 PM : Outperform Start Price: $1.03 RPRX Score: -15.05

nev

Recs

1
Member Avatar zzlangerhans (99.81) Submitted: 12/16/2015 12:03:48 AM : Outperform Start Price: $1.26 RPRX Score: -24.01

Unlike Threshold, I actually pulled the trigger on Repros puts prior to the inevitable harsh CRL and made a nice profit. Now I'm flagging the stock for an outperform as the market cap approaches cash. I think Repros has a good chance of rebounding somewhat in early 2016 with progress of phase II trials of Proellex for uterine fibroids. Phase II is generally a beneficial period for dubiously legitimate biopharmas like Repros as they award themselves every possible mulligan, leading to crushing defeat either in phase III or at the regulatory level. As with Threshold, this rebound depends on getting some lift otherwise the whole thing collapses into the muck of messy vulture financings and a reverse split.

Recs

0
Member Avatar DeathStock (26.20) Submitted: 10/23/2015 12:46:04 PM : Outperform Start Price: $6.08 RPRX Score: -75.70

Accidentally green thumbed this when I meant underperform. I've got to slow down when entering these picks. Hopefully I can break-even.

Recs

0
Member Avatar snowgoon42 (92.57) Submitted: 4/5/2015 11:33:08 AM : Outperform Start Price: $8.76 RPRX Score: -78.50

Bulls and Bears Trapper John

Recs

0
Member Avatar ashlandave (88.03) Submitted: 2/11/2015 12:29:57 PM : Outperform Start Price: $8.63 RPRX Score: -78.16

With NDA filed, decision due in month or two from FDA as to whether to accept it. Co. produces a drug which treats secondary hypo gonadism.

Recs

2
Member Avatar liszewski (99.96) Submitted: 10/21/2011 11:20:37 PM : Underperform Start Price: $4.03 RPRX Score: +126.25

Zonagen. lol.

Recs

1
Member Avatar rodessa (60.39) Submitted: 7/26/2011 7:12:18 AM : Underperform Start Price: $6.52 RPRX Score: +123.61

This company should take the same way as CBLI in the coming weeks as nothing at all can justify it's actual market price.To short without any moderation!!!

Recs

0
Member Avatar bridgeboy0 (98.79) Submitted: 2/4/2011 12:27:17 PM : Underperform Start Price: $3.30 RPRX Score: +114.36

From goldminingXpert

Recs

0
Member Avatar goldminingXpert (29.91) Submitted: 2/3/2011 1:25:49 PM : Underperform Start Price: $2.53 RPRX Score: +107.04

Still broke, still no drug. The Zonagen saga continues...

Recs

1
Member Avatar ravens9111 (< 20) Submitted: 12/24/2010 12:45:17 AM : Outperform Start Price: $1.44 RPRX Score: -87.49

Might be late to the party but I think even if it pulls back there is still more upside here.

Recs

1
Member Avatar panochey (< 20) Submitted: 1/19/2009 8:42:52 AM : Outperform Start Price: $45.96 RPRX Score: -218.34

Repros Therapeutics Inc. Announces That Proellex Significantly Reduced Pain in a U.S. Phase 2 Clinical Trial (Jan 2009)
Anything that helps Momma with the monthlies is gonna sell well. Oh, and minimal debt.

Recs

0
Member Avatar smallcapinvest (86.33) Submitted: 12/17/2008 11:14:11 AM : Outperform Start Price: $42.52 RPRX Score: -204.20

little gamble since fundamentals are so bad, but MACD looks good, STO is converging and I am hoping for a crossover

Recs

0
Member Avatar SanDieguito (24.16) Submitted: 12/3/2007 3:08:08 PM : Underperform Start Price: $30.60 RPRX Score: +126.87

down $2 to $7

Recs

0
Member Avatar ProphetOfProfits (43.22) Submitted: 7/27/2007 10:59:02 AM : Outperform Start Price: $52.80 RPRX Score: -128.75

Good clinical data re Proellex safety is a good enough reason for me to hop in again

Recs

0
Member Avatar jbfoolsgold (< 20) Submitted: 7/17/2007 10:47:22 PM : Outperform Start Price: $52.64 RPRX Score: -122.88

Strong development pipeline, product potentials and buyout potentials. It is just a matter of time before something happens to push to $20.

Recs

0
Member Avatar Molucre (71.58) Submitted: 2/15/2007 6:27:13 PM : Outperform Start Price: $43.80 RPRX Score: -131.17

Blockbuster drug with excellent Phase II data. Company will be bought out before the end of Phase III.

Recs

2
Member Avatar foolphighter (< 20) Submitted: 1/12/2007 1:46:41 AM : Outperform Start Price: $48.96 RPRX Score: -134.48

Micro biotech recently announced statistically significant results for its lead drug Proellex in two different indications and non-inferiority in another drug, Androxal.

with only 10M shares o/s, and just under a $1/share in cash, a financing appears to be in the company's near term future, but given the recent run-up in price, the dilution should help increase liquidity & institutional ownership while making it fairly painless for current shareholders. good speculative bet over the next 12 to 24 months.

Recs

0
Member Avatar BongoBilly (< 20) Submitted: 12/27/2006 7:13:26 AM : Outperform Start Price: $47.40 RPRX Score: -134.66

Significantly undervalued south of $25

Results 1 - 18 of 18

Featured Broker Partners